Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Operating Leases: 2023-2024

Historic Operating Leases for Axsome Therapeutics (AXSM) over the last 2 years, with Dec 2024 value amounting to $6.0 million.

  • Axsome Therapeutics' Operating Leases rose 257.78% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year increase of 257.78%. This contributed to the annual value of $6.0 million for FY2024, which is 14.06% down from last year.
  • Per Axsome Therapeutics' latest filing, its Operating Leases stood at $6.0 million for FY2024, which was down 14.06% from $7.0 million recorded in FY2023.
  • Axsome Therapeutics' Operating Leases' 5-year high stood at $7.0 million during FY2023, with a 5-year trough of $6.0 million in FY2024.
  • For the 2-year period, Axsome Therapeutics' Operating Leases averaged around $6.5 million, with its median value being $6.5 million (2023).
  • Data for Axsome Therapeutics' Operating Leases shows a maximum YoY decreased of 14.06% (in 2024) over the last 5 years.
  • Over the past 2 years, Axsome Therapeutics' Operating Leases (Yearly) stood at $7.0 million in 2023, then dropped by 14.06% to $6.0 million in 2024.